Bayesian Capital Management, LP Bluebird Bio, Inc. Transaction History

Bayesian Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.91 - $1.75 $36,803 - $70,775	40,443 New	40,443 $51,000
Q4 2022 Feb 14, 2023	BUY	$5.77 - $8.49 $121,169 - $178,290	21,000 Added 17.56%	140,600 $972,000
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $448,500 - $883,844	119,600 New	119,600 $757,000
Q1 2021 May 14, 2021	SELL	$16.59 - $33.89 $177,513 - $362,623	-10,700 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$27.5 - $37.92 $104,252 - $143,754	3,791 Added 54.87%	10,700 $463,000
Q3 2020 Nov 12, 2020	BUY	$34.44 - $43.75 $237,945 - $302,268	6,909 New	6,909 $373,000
Q1 2018 May 15, 2018	SELL	$105.8 - $150.94 $398,548 - $568,590	-3,767 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$81.25 - $130.7 $306,068 - $492,346	3,767	3,767 $671,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.